Conavi Medical (TSXV:CNVI) has announced that the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC) has published a peer-reviewed article detailing recent advances in hybrid...
PolTREG (WSE:PTG) has launched a Phase 2 clinical trial of PTG-007, a polyclonal autologous Treg cellular therapy, in children with presymptomatic Type-1 diabetes (T1D), following approval from the European Medicines...
Olema Oncology (NASDAQ:OLMA) has announced results from three preclinical studies demonstrating the robust anti-tumor activity of OP-3136 as a single agent and in combination with palazestrant. The results will be...
Ocugen (NASDAQ:OCGN) has announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of its Phase 1/2 clinical trial of OCU410ST GARDian for Stargardt disease. The GARDian...
SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential...
Closely-held MOBILion Systems has announced a novel, next-generation high-resolution mass spectrometry approach for complex sample analysis, delivering unprecedented speed, sensitivity, specificity, and quantitative...
Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...
PolyPid (NASDAQ:PYPD) has announced the publication of a study in the International Journal of Surgery (IJS), showcasing the full data set from its Phase 3 SHIELD I trial of D-PLEX, focused on preventing surgical site...
Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...
Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...
After completing its reverse takeover of Titan Medical on October 11th, Conavi Medical has completed its plan to voluntarily delist from the TSX and subsequently list on the TSX Venture Exchange (TSXV). Trading of...
Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors...
Theriva Biologics (NYSE American:TOVX) has announced that the European Commission (EC) has adopted the European Medicines Agency’s (EMA) recommendation to grant orphan medicinal product designation to its lead...
Eupraxia Pharmaceuticals (NASDAQ:EPRX; TSX:EPRX) has announced that the top-tier, peer-reviewed journal, Lancet Rheumatology, has published Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment...
Closely-held Ripple Therapeutics has announced evaluation and licensing agreements with Glaukos Corporation (NYSE:GKOS), enabling Glaukos to leverage Ripple’s proprietary technology platform to create sustained release...
Conavi Medical has completed its reverse takeover of Titan Medical (TSX:TMD; OTC:TMDIF). The combined company (the Resulting Issuer), which will voluntarily delist from the TSX on or about October 15, 2024, and...
Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced plans to present new data reinforcing the clinical significance of LUPKYNIS in the treatment of lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney...
Turnstone Biologics (NASDAQ:TSBX) has announced restructuring initiatives that include the strategic prioritization of its pipeline, a 60% workforce reduction, and changes to its leadership team, aimed at focusing...
Palisade Bio (NASDAQ:PALI) has announced that it has received a No Objection Letter from Health Canada for its Phase 1 clinical trial of PALI-2108 for the treatment of ulcerative colitis (UC). The orally-administered...
Clearmind Medicine (NASDAQ:CMND) has announced that it has received Institutional Review Board (IRB) approval from one of its U.S. clinical sites for part A of its Phase I/IIa clinical trial of CMND-100 for the...
SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to...
Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF) has announced the completion of patient enrollment in a pivotal clinical study evaluating its next-generation Perimeter B-Series OCT system, which combines proprietary...